Innate Pharma S.A.
NASDAQ:IPHABiotechnology
+$0.03 today
- Market cap
- $115.05M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
Volume 0.50M
Average 0.07M
IPHA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Innate Pharma S.A.NASDAQ: IPHA
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income grows 11.8% year over year
Q4 FY2025 net income of €27.63M (cash outflow) rose 11.8% year over year. Over 3 fiscal years it compounded at -5.4% a year.
Context
- Net income amounted to 1764.5% of revenue in FY2025, up 1372.5 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -€4.86M (-90.1%) for the fiscal year ending Dec 2026, a slowdown from the -0.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -€27.63M— QoQ
- Last fiscal yearDec 2025
- -€49.18M-0.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.8% | — | — |
| 1 year | -0.6% | -90.1% | -89.5 pp |
| 3-year CAGR | -5.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
EUR · from the cash flow
- Latest · FY2025
- (49.18M) EUR
- Year-over-year change
- +0.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (49.18M) | +0.6% |
| FY2024 | 2024-12-31 | (49.47M) | -553.5% |
| FY2023 | 2023-12-31 | (7.57M) | +87.0% |
| FY2022 | 2022-12-31 | (58.1M) | -10.0% |
| FY2021 | 2021-12-31 | (52.81M) | — |
Net Income vs competitors
How IPHA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.6% is the 5th highest of 8, against a peer median of +7.8%.
- Net income amounts to 1764.5% of revenue for IPHA, versus a peer median of 2416.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $84.53M USD | +68.1% | +22.9% | — | |
| LTM Mar 2026 | $68.36M USD | +31.7% | +2.6% | 3832.0% | |
| LTM Mar 2026 | CHF 64.16M CHF | +7.8% | — | — | |
| FY2025 | €49.18M EUR | -0.6% | -5.4% | 1764.5% | |
| LTM Mar 2026 | $44.76M USD | -8.4% | +5.8% | 8526.1% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $40.19M USD | -21.6% | +11.9% | — |
| LTM Dec 2025 | $35.34M USD | — | — | 48.6% | |
| LTM Mar 2026 | $31.7M USD | -25.4% | -22.3% | 1000.2% | |
| LTM Mar 2026 | $29.59M USD | +46.8% | +11.5% | — | |
| Peer median (excluding IPHA) | — | +7.8% | +8.6% | 2416.1% | |
Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (52.81M) | (58.1M) | (7.57M) | (49.47M) | (49.18M) |
| Depreciation & Amortization | 4.6M | 45.41M | 5.09M | 1.99M | 5.09M |
| Deferred Income Tax | (1.68M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.62M | 4.25M | 4.26M | 3.94M | 4.26M |
| Change in Working Capital | (9.88M) | (12.5M) | (32.09M) | 39.16M | (10.21M) |
| Accounts Receivables | 3.39M | (4.2M) | (13.67M) | 0 | 0 |
| Inventory | (6.27M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (946K) | (7.66M) | (3.89M) | 0 | 0 |
| Other Working Capital | (6.06M) | (636K) | (10.54M) | 39.16M | (10.21M) |
| Other Non-Cash Items | (1.3M) | 1.8M | (2.24M) | (2.53M) | (630.52K) |
| Operating Cash Flow | (58.46M) | (19.15M) | (32.56M) | (6.9M) | (50.67M) |
| Capital Expenditures | (1.33M) | (1.12M) | (2.35M) | (391K) | (134.47K) |
| Acquisitions (Net) | 7K | 0 | 0 | 0 | 4.8K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 3M | 22.77M | 9.59M | 13.51M |
| Other Investing Activities | 406K | (1K) | (1.79M) | 1K | (6.38M) |
| Investing Cash Flow | (917K) | 1.88M | 20.63M | 9.2M | 7M |
| Debt Repayment | 26.63M | (2.03M) | (2.36M) | (8.94M) | (8.56M) |
| Common Stock Issued | 499K | 198K | 395K | 2.93M | 14.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 187K | 198K | 395K | 2.93M | 0 |
| Financing Cash Flow | 26.82M | (1.83M) | (1.97M) | (6.01M) | 5.83M |
| Effect of Forex Changes | (483K) | (428K) | 274K | (505K) | 7.41M |
| Net Change in Cash | (33.04M) | (19.53M) | (13.62M) | (4.21M) | (30.44M) |
| Free Cash Flow | (59.79M) | (20.28M) | (34.91M) | (7.29M) | (50.81M) |
Innate Pharma S.A.
NASDAQ:IPHA
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.